TREM2 and Alzheimer disease: Proteolytic processing of TREM2 leads to the release of soluble fragments (sTREM2) that can be detected both in CSF and serum and which are increased in the CSF of AD patients, being correlated with levels of phosphorylated tau and tau pathology [185].